REVOLUTION Medicines Appoints Pharmaceutical Commercial Executive Elizabeth McKee Anderson To Board Of Directors

San Francisco/Redwood City, Calif., April 9, 2015 – REVOLUTION Medicines, Inc., a company focused on the discovery and development of innovative drugs derived by redesigning natural compounds, today announced the appointment of Elizabeth McKee Anderson, former worldwide vice president, infectious diseases and vaccines at Janssen Pharmaceuticals, Inc., to its board of directors.

"With more than three decades of experience in designing and executing growth strategies for leading pharmaceutical companies, Liz brings a wealth of applicable expertise to the REVOLUTION Medicines board," said Mark A. Goldsmith, M.D., Ph.D., president and chief executive officer. "Her deep knowledge in the global commercialization of innovative therapies, particularly those to treat infectious diseases, will help us advance our mission to translate nature's molecules into high-impact medicines for serious diseases."

Ms. Anderson previously served as the worldwide vice president and commercial leader in the infectious diseases and vaccines global commercial strategy organization at Janssen Pharmaceuticals, a Johnson & Johnson company. In this role, she led strategy, global commercialization and market access for the respiratory infections, HIV, sexually transmitted infections and bacterial pathogens portfolios. Ms. Anderson also helped develop and execute Janssen's first global vaccines strategy and played a key role in the acquisition of infectious disease company Crucell N.V. She held several leadership positions within Johnson & Johnson, including worldwide vice president, immunology & respiratory, global strategic marketing, as well as vice president of strategic planning and market research and vice president, global biologics strategic marketing at Centocor, an operating company of Johnson & Johnson. At Johnson & Johnson, Ms. Anderson and her teams developed and executed the global launch platforms for STELARA and SIMPONI, advanced next generation therapies which treat serious autoimmune diseases and collaborated with R&D partners on REMICADE, VELCADE and PROCRIT life cycle management. Prior to joining Johnson & Johnson, she was the vice president and general manager of Wyeth Vaccines from 1997 to 2002, where she played a key role in the launch of PREVNAR, a first-in-class vaccine that achieved $1 billion in sales within 18 months of introduction, the most successful launch in the 75-year history of Wyeth at the time.

"REVOLUTION Medicines' innovative approach to drug discovery holds exciting promise for enabling new treatments for serious diseases," said Ms. Anderson. "I look forward to collaborating with the company's talented leadership team and fellow board members to help deliver transformational products to patients."

About REVOLUTION Medicines

The mission of REVOLUTION Medicines is redesigning evolution's products to treat serious diseases. The company discovers and develops new drugs by reconfiguring natural substances that are inherently rich with biological function as a result of natural selection. REVOLUTION Medicines' innovative product engine is based on the REVEAL™ platform, which uses evolution's lessons to inform selection of chemical scaffolds, and the REVBLOCKS™ technology, a rapid, standardized and transformative synthesis process for assembling simple chemical "building blocks" into refined natural product-like structures with optimized pharmacologic and pharmaceutical properties. The company's first drug candidates are innovative small molecules that exploit and improve upon the properties of amphotericin B, a powerful, broad-spectrum antifungal compound found in nature that has avoided generating significant drug resistance in 50 years of clinical use. Headquartered in Redwood City, Calif. at the intersection of Silicon Valley and the birthplace of biotechnology, REVOLUTION Medicines is a private company financed by top-tier investor Third Rock Ventures. For more information, please visit www.revolutionmedicines.com.

Suggested Articles

Cancer biotech Zentalis Pharmaceuticals priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.

The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.

Johnson & Johnson is paying Fate Therapeutics $50 million upfront to collaborate on up to four CAR NK and CAR-T cell therapies.